Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

A Blauvelt; B Strober; R Langley; S Kavanagh; C Arendt; M Boehnlein; M Lebwohl; K Reich

doi:10.25251/skin.3.supp.39

A Blauvelt

Oregon Medical Research Center, Portland, OR, USA

B Strober

University of Connecticut Health Center, Farmington, CT, USA; Probity Medical Research, Waterloo, Ontario, Canada

R Langley

Dalhousie University, Nova Scotia, Canada

S Kavanagh

UCB Pharma, Raleigh, NC, USA

C Arendt

UCB Pharma, Brussels, Belgium

M Boehnlein

UCB Pharma, Monheim, Germany

M Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY, USA

K Reich

SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany

Keywords

psoriasis, certolizumab

Abstract

Abstract not available.

References

1. Kurd SK and Gelfand JM. JAAD. 2009;60:218–24

2. Rachakonda TD. et al. 2014;70:512–6

3. Certolizumab Pegol Prescribing Information. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf [Last accessed: May 2019]

4. Gottlieb AB. et al. JAAD. 2018;79:302–14.e6

5. Lebwohl M. et al. JAAD. 2018;79:266–76.e5.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.39

How to Cite

Blauvelt, A., Strober, B., Langley, R., Kavanagh, S., Arendt, C., Boehnlein, M., Lebwohl, M., & Reich, K. (2019). Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal of Cutaneous Medicine, 3, S39. https://doi.org/10.25251/skin.3.supp.39

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

E von Stebut, K Reich, D Thaci, W Koenig, A Pinter, A Korber, T Rassaf, A Waisman, V Mani, D Yates, J Frueh, C Sieder, N Melzer, T Gori, Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich, Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, F Brock, C Arendt, M Boehnlein, K Reich, Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
E Guttman-Yassky, A Blauvelt, L Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson, Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
D Tha?i, A Blauvelt, K Reich, RB Warren, V Piguet, F Brock, F Fierens, V Ciaravino, M Lebwohl, Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
A Blauvelt, B Strober, R Langley, D Burge, L Pisenti, M Yassine, S Kavanagh, C Arendt, R Rolleri, K Reich, Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich, Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
A.B. Gottlieb, D Thaci, C Leonardi, Y Poulin, S Kavanagh, M Boehnlein, K Reich, Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
K Gordon, RB Warren, AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich, Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich, Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)